Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tissue Adhesions | 3 | 2015 | 30 | 1.210 |
Why?
|
| Lactic Acid | 4 | 2014 | 166 | 0.830 |
Why?
|
| Pancreatic Neoplasms | 2 | 2021 | 738 | 0.830 |
Why?
|
| Protein C | 4 | 2016 | 21 | 0.820 |
Why?
|
| Protein C Deficiency | 2 | 2019 | 12 | 0.740 |
Why?
|
| Cytological Techniques | 1 | 2021 | 17 | 0.710 |
Why?
|
| Carcinoma, Papillary | 1 | 2021 | 96 | 0.700 |
Why?
|
| Polyphosphates | 3 | 2016 | 9 | 0.670 |
Why?
|
| Gardner Syndrome | 1 | 2019 | 2 | 0.630 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2019 | 29 | 0.630 |
Why?
|
| Malaria, Falciparum | 1 | 2020 | 72 | 0.620 |
Why?
|
| Plasmodium falciparum | 1 | 2020 | 97 | 0.620 |
Why?
|
| Nanofibers | 4 | 2014 | 21 | 0.620 |
Why?
|
| Purpura Fulminans | 1 | 2019 | 7 | 0.620 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2019 | 45 | 0.610 |
Why?
|
| Thrombophilia | 1 | 2019 | 42 | 0.590 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2019 | 76 | 0.590 |
Why?
|
| Inflammation Mediators | 3 | 2015 | 259 | 0.580 |
Why?
|
| Antithrombin III | 1 | 2018 | 28 | 0.560 |
Why?
|
| Heparin | 2 | 2018 | 230 | 0.530 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 46 | 0.530 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 185 | 0.490 |
Why?
|
| Polyglycolic Acid | 2 | 2014 | 26 | 0.480 |
Why?
|
| Peritoneal Diseases | 1 | 2015 | 8 | 0.470 |
Why?
|
| Tissue Engineering | 4 | 2014 | 184 | 0.460 |
Why?
|
| HMGB1 Protein | 2 | 2016 | 27 | 0.460 |
Why?
|
| Glycation End Products, Advanced | 2 | 2016 | 30 | 0.460 |
Why?
|
| Receptors, Purinergic P2Y1 | 1 | 2013 | 10 | 0.430 |
Why?
|
| Receptor for Advanced Glycation End Products | 1 | 2013 | 32 | 0.420 |
Why?
|
| Tissue Scaffolds | 3 | 2014 | 85 | 0.400 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 652 | 0.390 |
Why?
|
| Losartan | 1 | 2012 | 36 | 0.380 |
Why?
|
| Durapatite | 1 | 2011 | 15 | 0.380 |
Why?
|
| Heptanoic Acids | 1 | 2012 | 79 | 0.370 |
Why?
|
| Endothelial Cells | 5 | 2020 | 544 | 0.370 |
Why?
|
| Bone Development | 1 | 2011 | 60 | 0.360 |
Why?
|
| Inflammation | 6 | 2018 | 1595 | 0.360 |
Why?
|
| Postoperative Complications | 2 | 2015 | 3178 | 0.360 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2012 | 138 | 0.350 |
Why?
|
| Pyrroles | 1 | 2012 | 187 | 0.340 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 3 | 2016 | 109 | 0.340 |
Why?
|
| Histones | 1 | 2013 | 573 | 0.320 |
Why?
|
| Immunohistochemistry | 3 | 2021 | 1765 | 0.320 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 1409 | 0.310 |
Why?
|
| Bone Regeneration | 3 | 2014 | 24 | 0.310 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2010 | 152 | 0.300 |
Why?
|
| Stem Cell Transplantation | 1 | 2010 | 252 | 0.280 |
Why?
|
| Thrombin | 3 | 2016 | 63 | 0.270 |
Why?
|
| Antithrombins | 2 | 2020 | 59 | 0.260 |
Why?
|
| Pancreas | 2 | 2021 | 232 | 0.250 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 757 | 0.230 |
Why?
|
| Stem Cells | 3 | 2014 | 754 | 0.210 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2016 | 456 | 0.200 |
Why?
|
| Mice | 8 | 2018 | 19055 | 0.200 |
Why?
|
| Animals | 13 | 2018 | 36557 | 0.200 |
Why?
|
| Liver | 1 | 2010 | 1879 | 0.190 |
Why?
|
| SOXC Transcription Factors | 1 | 2021 | 13 | 0.190 |
Why?
|
| Signal Transduction | 5 | 2018 | 4934 | 0.180 |
Why?
|
| Blood Coagulation Tests | 2 | 2019 | 62 | 0.180 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2021 | 121 | 0.180 |
Why?
|
| Mutation | 4 | 2019 | 6338 | 0.180 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2021 | 32 | 0.170 |
Why?
|
| Humans | 20 | 2021 | 134156 | 0.170 |
Why?
|
| Histidine | 1 | 2020 | 75 | 0.160 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 268 | 0.160 |
Why?
|
| Cell Differentiation | 5 | 2014 | 2045 | 0.160 |
Why?
|
| Polyps | 1 | 2020 | 44 | 0.160 |
Why?
|
| Blood Coagulation | 3 | 2015 | 134 | 0.160 |
Why?
|
| Antigens, Protozoan | 1 | 2020 | 81 | 0.160 |
Why?
|
| Insulin | 2 | 2018 | 1260 | 0.160 |
Why?
|
| Endoscopic Mucosal Resection | 1 | 2020 | 74 | 0.150 |
Why?
|
| Protozoan Proteins | 1 | 2020 | 135 | 0.150 |
Why?
|
| HEK293 Cells | 2 | 2018 | 825 | 0.140 |
Why?
|
| Polymers | 3 | 2014 | 118 | 0.140 |
Why?
|
| Plasma Exchange | 1 | 2018 | 89 | 0.130 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 316 | 0.130 |
Why?
|
| Receptor, PAR-1 | 1 | 2016 | 2 | 0.130 |
Why?
|
| beta-Arrestin 2 | 1 | 2016 | 12 | 0.130 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2016 | 66 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 3 | 2016 | 4879 | 0.130 |
Why?
|
| Osteogenesis | 3 | 2013 | 168 | 0.130 |
Why?
|
| Structure-Activity Relationship | 1 | 2018 | 611 | 0.130 |
Why?
|
| Cyclin D1 | 1 | 2016 | 123 | 0.130 |
Why?
|
| Hyperlipidemias | 1 | 2018 | 198 | 0.130 |
Why?
|
| Skin | 1 | 2019 | 545 | 0.120 |
Why?
|
| Protein Conformation | 1 | 2018 | 873 | 0.120 |
Why?
|
| Body Weight | 2 | 2010 | 1041 | 0.120 |
Why?
|
| Kinetics | 1 | 2018 | 1357 | 0.120 |
Why?
|
| Inorganic Chemicals | 1 | 2015 | 1 | 0.120 |
Why?
|
| Polyesters | 2 | 2014 | 43 | 0.120 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 721 | 0.120 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 207 | 0.120 |
Why?
|
| Sulfones | 2 | 2013 | 75 | 0.120 |
Why?
|
| Adipose Tissue | 3 | 2013 | 510 | 0.120 |
Why?
|
| Infusions, Parenteral | 1 | 2015 | 100 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2014 | 1310 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2020 | 615 | 0.110 |
Why?
|
| Adenosine A2 Receptor Agonists | 1 | 2014 | 15 | 0.110 |
Why?
|
| Binding Sites | 1 | 2018 | 1384 | 0.110 |
Why?
|
| Zinc Compounds | 1 | 2014 | 6 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 158 | 0.110 |
Why?
|
| Peritonitis | 1 | 2015 | 80 | 0.110 |
Why?
|
| Silicates | 1 | 2014 | 11 | 0.110 |
Why?
|
| Antigens, CD | 1 | 2016 | 451 | 0.110 |
Why?
|
| Nasal Septum | 1 | 2014 | 18 | 0.110 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2013 | 232 | 0.110 |
Why?
|
| Receptors, Cell Surface | 1 | 2016 | 497 | 0.110 |
Why?
|
| Chondrocytes | 1 | 2014 | 51 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 490 | 0.110 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 219 | 0.110 |
Why?
|
| Cell Membrane Permeability | 1 | 2013 | 77 | 0.110 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2014 | 85 | 0.110 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2013 | 59 | 0.100 |
Why?
|
| Point Mutation | 1 | 2015 | 362 | 0.100 |
Why?
|
| Adenosine | 1 | 2014 | 140 | 0.100 |
Why?
|
| Protein Binding | 1 | 2018 | 1859 | 0.100 |
Why?
|
| Protein Structure, Secondary | 1 | 2014 | 256 | 0.100 |
Why?
|
| Models, Animal | 2 | 2014 | 486 | 0.100 |
Why?
|
| Cell Movement | 2 | 2014 | 920 | 0.100 |
Why?
|
| Male | 9 | 2018 | 66127 | 0.100 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2013 | 145 | 0.100 |
Why?
|
| Thrombosis | 1 | 2018 | 547 | 0.100 |
Why?
|
| Mesoderm | 1 | 2013 | 113 | 0.100 |
Why?
|
| Injections, Intraperitoneal | 1 | 2012 | 74 | 0.100 |
Why?
|
| Adult Stem Cells | 1 | 2012 | 55 | 0.100 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2012 | 52 | 0.090 |
Why?
|
| Cellulose, Oxidized | 1 | 2011 | 2 | 0.090 |
Why?
|
| Endothelium, Vascular | 1 | 2015 | 522 | 0.090 |
Why?
|
| Glass | 1 | 2011 | 12 | 0.090 |
Why?
|
| Peritoneum | 1 | 2011 | 40 | 0.090 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2012 | 139 | 0.090 |
Why?
|
| Rats | 3 | 2014 | 3890 | 0.090 |
Why?
|
| Mice, Inbred Strains | 1 | 2011 | 323 | 0.090 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2012 | 121 | 0.090 |
Why?
|
| Calcium | 2 | 2013 | 1148 | 0.090 |
Why?
|
| Abdomen | 1 | 2011 | 136 | 0.090 |
Why?
|
| Biocompatible Materials | 1 | 2011 | 129 | 0.090 |
Why?
|
| Growth | 1 | 2010 | 106 | 0.080 |
Why?
|
| Streptozocin | 1 | 2010 | 28 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2018 | 872 | 0.080 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 4808 | 0.080 |
Why?
|
| Prognosis | 1 | 2019 | 5086 | 0.080 |
Why?
|
| Body Height | 1 | 2010 | 230 | 0.080 |
Why?
|
| Glucose Tolerance Test | 1 | 2010 | 227 | 0.080 |
Why?
|
| DNA Primers | 1 | 2010 | 672 | 0.080 |
Why?
|
| Cytokines | 1 | 2015 | 1401 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2012 | 2915 | 0.070 |
Why?
|
| NF-kappa B | 3 | 2015 | 482 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 867 | 0.070 |
Why?
|
| Body Composition | 1 | 2010 | 562 | 0.070 |
Why?
|
| Mice, Knockout | 1 | 2015 | 4016 | 0.060 |
Why?
|
| Blood Glucose | 1 | 2010 | 1196 | 0.060 |
Why?
|
| Base Sequence | 1 | 2010 | 3180 | 0.060 |
Why?
|
| Protein Transport | 2 | 2016 | 390 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2010 | 1719 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2014 | 3188 | 0.050 |
Why?
|
| Cell Adhesion | 2 | 2014 | 361 | 0.050 |
Why?
|
| Retrospective Studies | 1 | 2021 | 17540 | 0.050 |
Why?
|
| Cell Separation | 2 | 2012 | 234 | 0.040 |
Why?
|
| Fetal Blood | 2 | 2012 | 178 | 0.040 |
Why?
|
| Cell Proliferation | 3 | 2014 | 2563 | 0.040 |
Why?
|
| Bone Marrow Cells | 2 | 2012 | 275 | 0.040 |
Why?
|
| Endoscopy | 1 | 2020 | 287 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 162 | 0.030 |
Why?
|
| Gene Expression | 2 | 2013 | 1621 | 0.030 |
Why?
|
| Endothelial Protein C Receptor | 1 | 2016 | 5 | 0.030 |
Why?
|
| G-Protein-Coupled Receptor Kinase 5 | 1 | 2016 | 5 | 0.030 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2016 | 5 | 0.030 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2016 | 21 | 0.030 |
Why?
|
| Cytoprotection | 1 | 2016 | 39 | 0.030 |
Why?
|
| Dishevelled Proteins | 1 | 2016 | 45 | 0.030 |
Why?
|
| Membrane Microdomains | 1 | 2016 | 63 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2016 | 120 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2015 | 31 | 0.030 |
Why?
|
| Thrombomodulin | 1 | 2015 | 23 | 0.030 |
Why?
|
| beta Catenin | 1 | 2016 | 232 | 0.030 |
Why?
|
| Receptor, Adenosine A2B | 1 | 2014 | 11 | 0.030 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2014 | 11 | 0.030 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2014 | 11 | 0.030 |
Why?
|
| E-Selectin | 1 | 2014 | 43 | 0.030 |
Why?
|
| Ceramics | 1 | 2014 | 6 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2016 | 838 | 0.030 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2014 | 48 | 0.030 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 78 | 0.030 |
Why?
|
| Tensile Strength | 1 | 2014 | 46 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2014 | 77 | 0.030 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2015 | 173 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 1310 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2014 | 149 | 0.030 |
Why?
|
| Surface Properties | 1 | 2014 | 96 | 0.030 |
Why?
|
| Chondrogenesis | 1 | 2014 | 29 | 0.030 |
Why?
|
| Skull Fractures | 1 | 2014 | 43 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2014 | 247 | 0.030 |
Why?
|
| Cyclic AMP | 1 | 2014 | 263 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2014 | 74 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2014 | 94 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2013 | 69 | 0.030 |
Why?
|
| Camelus | 1 | 2013 | 5 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2014 | 650 | 0.030 |
Why?
|
| RNA Interference | 1 | 2014 | 548 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2016 | 1713 | 0.020 |
Why?
|
| Transfection | 1 | 2014 | 1096 | 0.020 |
Why?
|
| Adipogenesis | 1 | 2012 | 84 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2014 | 311 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2013 | 294 | 0.020 |
Why?
|
| Osteonectin | 1 | 2011 | 6 | 0.020 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2011 | 12 | 0.020 |
Why?
|
| Osteocalcin | 1 | 2011 | 50 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2011 | 104 | 0.020 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2011 | 88 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1740 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2011 | 130 | 0.020 |
Why?
|
| Rural Health | 1 | 2010 | 52 | 0.020 |
Why?
|
| Adult | 3 | 2018 | 31945 | 0.020 |
Why?
|
| Iran | 1 | 2010 | 93 | 0.020 |
Why?
|
| Urban Health | 1 | 2010 | 79 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2013 | 837 | 0.020 |
Why?
|
| Reference Values | 1 | 2010 | 741 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2010 | 920 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2198 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2012 | 951 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 1923 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 1909 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2015 | 5222 | 0.010 |
Why?
|
| Biomarkers | 1 | 2014 | 3434 | 0.010 |
Why?
|
| Adolescent | 2 | 2014 | 20624 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 2669 | 0.010 |
Why?
|
| Age Factors | 1 | 2010 | 2998 | 0.010 |
Why?
|
| Young Adult | 1 | 2014 | 9944 | 0.010 |
Why?
|
| Female | 2 | 2015 | 71928 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2010 | 14884 | 0.010 |
Why?
|
| Child | 1 | 2010 | 25890 | 0.010 |
Why?
|